Robert W. Baird Has Lowered Expectations for ICON Public (NASDAQ:ICLR) Stock Price

ICON Public (NASDAQ:ICLR - Free Report) had its price target lowered by Robert W. Baird from $249.00 to $225.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a neutral rating on the medical research company's stock.

Several other brokerages have also commented on ICLR. StockNews.com lowered shares of ICON Public from a "buy" rating to a "hold" rating in a report on Thursday, September 19th. JPMorgan Chase & Co. decreased their price target on shares of ICON Public from $375.00 to $280.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. Redburn Atlantic began coverage on shares of ICON Public in a research note on Monday, October 14th. They set a "neutral" rating and a $311.00 price objective for the company. Barclays cut their price objective on shares of ICON Public from $330.00 to $275.00 and set an "overweight" rating for the company in a report on Friday, October 25th. Finally, Leerink Partnrs upgraded ICON Public to a "strong-buy" rating in a report on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $292.45.

ICON Public Stock Up 4.1 %

Shares of ICLR stock traded up $8.07 during trading hours on Wednesday, reaching $203.67. 1,837,087 shares of the company's stock were exchanged, compared to its average volume of 719,180. The stock has a market cap of $16.80 billion, a PE ratio of 21.81, a PEG ratio of 1.40 and a beta of 1.25. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock's fifty day moving average price is $263.10 and its two-hundred day moving average price is $299.72. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analysts' expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the business earned $3.10 EPS. Research analysts predict that ICON Public will post 13.43 EPS for the current year.

Hedge Funds Weigh In On ICON Public

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. SkyView Investment Advisors LLC acquired a new position in ICON Public during the 1st quarter worth approximately $1,021,000. EverSource Wealth Advisors LLC increased its holdings in shares of ICON Public by 17.4% in the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company's stock valued at $95,000 after purchasing an additional 42 shares during the period. GAMMA Investing LLC lifted its holdings in shares of ICON Public by 50.0% during the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company's stock worth $82,000 after purchasing an additional 87 shares during the period. ORG Partners LLC acquired a new position in ICON Public in the 2nd quarter valued at $59,000. Finally, Liontrust Investment Partners LLP raised its holdings in ICON Public by 19.5% during the second quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company's stock worth $37,531,000 after purchasing an additional 19,546 shares in the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.